ClinicalTrials.gg
CompletedNCT03857425Updated Sep 25, 2019

Helicobacter Pylori Eradication With Clostridum Butyricum Capsule and Bacillus Coagulans Tablets

A Phase 4 interventional study of Clostridum Butyricum Capsule and Bacillus Coagulans Tablets in Gastritis, H Pylori Infection and Dyspepsia, sponsored by Xijing Hospital of Digestive Diseases. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-09-25.

Sponsored by Xijing Hospital of Digestive Diseases · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Gastritis with a site in China — 7 open to participants now, 7 under way, none of them phase 3. Gastritis · China.

Enrollment
19th of 22
150 · median 520
Started
2019
the only one that year
Phase 4
13 of 31
2 open now
Registered
12th of 31
by date
Lead sponsor
9 of 31
Xijing Hospital of Digestive Diseases

Among the 31 studies in Gastritis with a site in China, this one is the 19th largest by enrollment of the 22 interventional ones that give a count, is the only one that started in 2019, is one of 13 in phase 4, and was the 12th registered.

Gastritis

136 studies on the registry are indexed under Gastritis; 24 are open to participants now.

Browse Gastritis studies →

Open to participants now

7 of the 31 studies in Gastritis with a site in China are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 11 Gastritis studies recruiting now, 6 (55%) set no upper age limit and 5 (45%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Gastritis with a site in China, or all of them as a file.
02

Study summary

This study aims at evaluating efficacy Clostridum Butyricum Capsule and Bacillus Coagulans Tablets in H. pylori eradication. It is hypothesized that Clostridum Butyricum Capsule , Bacillus Coagulans Tablets monotherapy or Clostridum Butyricum Capsule plus Bacillus Coagulans may have some positive effect on H. pylori eradication.

Read the detailed description

The study will include three phases: screening, treatment and follow-up. Screening: during this phase subjects eligibility will be evaluated after informed consent signature. Endoscopy and Urea Breath test will be performed in addition to the baseline routine evaluations.

Treatment: Subjects are randomly assigned to treatment and will be treated for 8weeks.

Follow-up: includes one visits. Eradication of H. Pylori will be confirmed through urea breath test(UBT).

03

Conditions studied

  • Gastritis
  • H Pylori Infection
  • Dyspepsia

Keywords

  • Gastritis
  • H Pylori Infection
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 18\~70,both gender.
  2. Patients with upper gastrointestinal symptoms and with documented H.pylori infection.
  3. Patients are willing to receive eradication treatment.
  4. Women are eligible if they are not pregnant or nursing, and if they are of they are required to use medically acceptable for the duration of the study and 30 days thereafter.

Exclusion criteria

Exclusion Criteria:

  1. Patients are excluded if they have previously used antibiotics to eradicate adequately recorded infection with H. pylori.
  2. to study drugs.
  3. Substantial organ impairment, severe or unstable cardiopulmonary or endocrine disease.
  4. Constant use of anti-ulcer drugs ( including taking proton-pump. inhibitors(PPI) within 2 weeks before the [13C] urea breath test), antibiotics or bismuth complexes (more than 3 times /1 month before screening).
  5. Pregnant or lactating women.
  6. Patients were diagnosed with gastroduodenal ulcer and MALT lymphoma.
  7. Underwent upper gastrointestinal Surgery.
  8. Patients with Barrett esophageal or highly atypical hyperplasia, have symptom of dysphagia.
  9. Evidence of bleeding or iron efficiency anemia.
  10. A history of .
  11. Drug or alcohol abuse history in the past 1 year.
  12. Systemic use of , non steroidal anti-inflammatory drugs, anticoagulants, aggregation inhibitors (except the use of aspirin for less than 100 mg/d).
  13. Enrolled in other clinical trials in the past 3 months.
  14. Patients who has psychological problem or poor compliance.
  15. Refuse to sign .
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    Clostridum Butyricum Capsule

    Clostridum Butyricum Capsule 3\*420mg, twice daily for 8 weeks

    Drug: Clostridum Butyricum Capsule

  • Experimental
    Bacillus Coagulans Tablets

    Bacillus Coagulans Tablets 3\*350mg, three times daily for 8 weeks

    Drug: Bacillus Coagulans Tablets

  • Experimental
    Clostridum Butyricum Capsule plus Bacillus Coagulans Tablets

    Clostridum Butyricum Capsule 3\*420mg, twice daily for 8 weeks and Bacillus Coagulans Tablets 3\*350mg, three times daily for 8 weeks

    Drug: Clostridum Butyricum Capsule plus Bacillus Coagulans Tablets

Interventions

  • DrugClostridum Butyricum Capsule

    Clostridum Butyricum Capsule 3\*420mg,twice daily for 8 weeks

  • DrugHeyndrickxia coagulansStudies of Heyndrickxia coagulansHeyndrickxia coagulans pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Bacillus Coagulans Tablets 3\*350mg, three times daily for 8 weeks

  • DrugClostridum Butyricum Capsule plus Bacillus Coagulans Tablets

    Clostridum Butyricum Capsule 3\*420mg, twice daily for 8 weeks and Bacillus Coagulans Tablets 3\*350mg, three times daily for 8 weeks

06

What researchers measure

Primary outcomes

  1. helicobacter pylori eradication H.pylori eradication

    Rate of H.pylori eradication Assessed by urea breath test,rapid urease test or helicobacter pylori stool antigen test after the end of treatment.

    Time frame: 8 weeks

07

Study locations

1 site
  • Xijing Hosipital of Digestive Disease
    Xi'an, Shaanxi 710032, China
08

References and documents

Publications

  • Zhang J, Guo J, Li D, Chen M, Liu J, Feng C, He Q, Zhao J, Zhang L, Chen J, Shi Y. The efficacy and safety of Clostridium butyricum and Bacillus coagulans in Helicobacter pylori eradication treatment: An open-label, single-arm pilot study. Medicine (Baltimore). 2020 Nov 6;99(45):e22976. doi: 10.1097/MD.0000000000022976. PubMed 33157939 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Aug 2019, 5 months.

Of 14 phase 4 interventional studies under Gastritis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2019
First posted
Feb 28, 2019
StartActual
Mar 1, 2019
Primary completionActual
Aug 31, 2019
CompletionActual
Sep 15, 2019
Last update
Sep 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03857425
Lead sponsor
Xijing Hospital of Digestive Diseases
Responsible party
Yongquan Shi (Principal Investigator, Clinical Professor, Xijing Hospital of Digestive Diseases) — Principal investigator
First posted
Feb 28, 2019
Start date
Mar 1, 2019
Primary completion
Aug 31, 2019
Completion
Sep 15, 2019
Last update
Sep 25, 2019

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Heyndrickxia coagulans

Start the discussion